MedPath
HSA Product

RETROVIR ORAL SOLUTION 10 mg/ml

Product approved by Health Sciences Authority (SG)

Basic Information

RETROVIR ORAL SOLUTION 10 mg/ml

SYRUP

Regulatory Information

SIN07527P

October 26, 1993

Prescription Only

Therapeutic

ORAL

August 10, 2023

June 3, 2025

Company Information

GLAXOSMITHKLINE PTE LTD

GLAXOSMITHKLINE PTE LTD

Active Ingredients

ZIDOVUDINE

Strength: 10 mg/ml

Detailed Information

Contraindications

**Contraindications** _RETROVIR_ is contraindicated in patients known to be hypersensitive to zidovudine, or to any of the components of the formulations. _RETROVIR_ should not be given to patients with abnormally low neutrophil counts (less than 0.75 x 109/l) or abnormally low haemoglobin levels (less than 7.5 g/dl or 4.65 mmol/l) ( _see Warnings and Precautions_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).

Indication Information

**Indications** _RETROVIR_ is indicated in combination with other antiretroviral agents for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and children.

© Copyright 2025. All Rights Reserved by MedPath